Patient characteristic with preoperative and postoperative data
| Age | Sex | Surgical intervention | Δ | IOP/VA | F | Complications | |
|---|---|---|---|---|---|---|---|
| Preop | Postop | ||||||
| 69 | m | Phako, Trab/MMC, io visco, transconjunctival sutures | 3 | 5/0.4 | 10/1.0 | 18 | Antiglaucomatous topical medication |
| 89 | f | Phako, Trab/MMC, io visco, transconjunctival sutures | 6 | 7/0.1 | 14/0.6 | 6 | – |
| 82 | m | Trab/MMC, 2× io visco | 4 | 5/0.25 | 8/0.5 | 6 | – |
| 76 | f | Phako, Trab/MMC, 2× io visco | 5 | 5/0.2 | 8/0.6 | 12 | – |
| 73 | m | Phako, Trab/MMC, laser suture lysis | 2 | 3/0.25 | 13/0.25 | 4 | – |
| 73 | f | Trab/MMC | 1 | 2/0.4 | 9/0.6 | 7 | – |
| 69 | f | Phako, Trab/MMC, io visco | 4 | 5/0.5 | 7/1.0 | 4 | – |
| 80 | f | Phako, trab/MMC, io visco | 1 | 4/0.05 | 11/0.4 | 2 | Additional compression sutures, persisting choroidal detachment, pericard patch |
| 56 | m | Trab/MMC | 72 | 6/0.1 | 10/0.16 | 4 | Persisting choroidal folds |
| 76 | f | Trab/MMC | 5 | 3/0.4 | 6/0.4 | 2 | – |
| 63 | m | Vitrectomy, Trab/MMC | 8 | 3/0.6 | 15/1.0 | 9 | Preoperative leakage—postoperative localised implant exposure, secondary conjunctival advancement |
| 50 | m | Trab/MMC, 5-FU injection | 11 | 5/0.2 | 9/0.2 | 11 | Preoperative leakage—postoperative corneal dellen, antiglaucomatous topical medication |
Δ , time between trabeculectomy and secondary CGM implantation in months.
Age in years; m, male; f, female; CGM, collagen glycosaminoglycan matrices; F, follow-up in months; FU, fluorouracil; io visco, intraocular injection of viscoelastic material; IOP, intraocular pressure in mm Hg (before CGM surgery and at the final follow-up visit); Phako, Phacoemulsification with intraocular lens implantation; Trab/MMC, trabeculectomy with mitomycin C; VA, visual acuity (as decimal fraction before CGM surgery and at the final follow-up visit).